New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
11:44 EDTGILD, PCLNStocks with call strike movement; PCLN GILD
Priceline (PCLN) July 1490 call option implied volatility increased 6% to 35, Gilead (GILD) August 82.5 call option implied volatility increased 5% to 82.5 according to IVolatility.
News For PCLN;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
08:32 EDTPCLNPriceline acquires AS Digital in Australia
Subscribe for More Information
September 2, 2015
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
08:33 EDTGILDGilead says investigation of F/TAF-based regimens met primary 48-week objective
Subscribe for More Information
August 31, 2015
17:28 EDTPCLNHotels add perks to compete with Priceline, Expedia, NY Times says
Subscribe for More Information
August 26, 2015
17:06 EDTGILDGilead AMBITION study results published in New England Journal of Medicine
Gilead Sciences (GILD) announced detailed results from the AMBITION study. In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50% compared to the pooled Letairis and tadalafil monotherapy arm. These data were published in The New England Journal of Medicine. Letairis, a selective endothelin type-A receptor antagonist, and tadalafil, a PDE5 inhibitor, are each approved in the United States, the European Union and other countries as once-daily treatments for patients with pulmonary arterial hypertension with WHO/NYHA functional class II and III symptoms. Letairis is indicated in the U.S. to improve exercise ability and delay clinical worsening and in the EU under the tradename Volibris to improve exercise capacity. Tadalafil 40 mg is indicated in the U.S. and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects. However, combination use with Letairis and tadalafil is currently not approved.
10:12 EDTPCLNGoogle climbs after Goldman upgrade, Cantor endorsement
The shares of Google (GOOG, GOOGL) are rallying after Goldman Sachs upgraded the search giant's stock and Cantor Fitzgerald named the stock as one of the top five Internet names to buy amid the market's recent selloff. WHAT'S NEW: Google is in the early innings of a long-term margin expansion process as the search giant intensifies its focus on cost cutting, Goldman analyst Heather Bellini wrote in a note to investors today. Moreover, after conducting checks, Bellini is more upbeat on the company's ability to increase its monetization of YouTube and mobile search. The analyst, who believes that cost cutting combined with the increased monetization is starting to move the needle for the company, hiked her price target on Google's Class A stock to $800 from $660, upgraded the stock and added the shares to Goldman's Americas Conviction List. Meanwhile, Cantor Fitzgerald analyst Youssef Squali named Google as one of his top five Internet stocks to buy amid the market's recent volatility. Google is "relatively resilient," given its 91% share of the global search market as of July and its $61B of net cash as of the end of Q2, the analyst believes. Moreover, the company has virtually no exposure to China and its new corporate structure should improve its transparency, Squali believes. He kept a $720 price target and Buy rating on the stock. WHAT'S NOTABLE: The other four companies on Squali's list of top Internet stocks are Amazon (AMZN), Priceline (PCLN), Facebook (FB), and Alibaba (BABA). PRICE ACTION: In early trading, Google's Class A shares rose 4.4% to $640 and its Class C shares advanced nearly 5% to $610.
07:25 EDTPCLNCantor names top five Internet names to buy during selloff
Cantor Fitzgerald analyst Youssef Squali said he "won't attempt to call the bottom" but identified his top five Internet and Media names to buy amid the recent market volatility, all of which have dominance in their respective markets, higher than peer level growth and valuations that he views as reasonable. Squali, who noted that he views concerns over macro risks and China to be overblown, called out Google (GOOG), Amazon (AMZN), Priceline (PCLN), Facebook (FB) and Alibaba (BABA) as having an attractive risk/reward given the selloff in recent sessions. The firm has Buy ratings on all five of the stocks named above.
August 25, 2015
19:34 EDTGILDExperts tell White House to expand use of Hepatitis C drugs, NYT says
Health care experts from the Public Health Service and the Advisory Council on H.I.V./AIDS have recommended that Medicaid officials expand the use of costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni, reports the New York Times, citing correspondence sent to the White House. The advisory council said current usage limitations on the drugs are "unreasonable," but it also suggested that manufacturers disclose drug development costs in the face of the significant price tags on modern Hepatitis C treatments. Reference Link
12:51 EDTPCLNPriceline August weekly volatility increases on wide price movement
Priceline August weekly call option implied volatility is at 45, September is at 35; compared to its 52-week range of 17 to 41, suggesting large near term price movement.
11:23 EDTPCLNAnalyst says Priceline undervalued, looks poised to outperform
Subscribe for More Information
07:45 EDTPCLNPriceline shares still undervalued with issues stabilizing, says Piper Jaffray
Subscribe for More Information
August 24, 2015
13:36 EDTGILDBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use